OriGene Antibodies in recent publications
ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial British Journal of Cancer 109, 2096-2105 (15 October 2013)
Recruitment of TLR adapter TRIF to TLR4 signaling complex is mediated by the second helical region of TRIF TIR domain PNAS, vol. 110 no. 47: 19036–19041
FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer Cancer Res. 2013 Sep 1;73(17):5416-25
Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions.
Cancer Prevention Research, Jul 2013; 6: 666 - 674.
|View All Citations >>||
Home Gene of the month ERG|
ERG Is A Prostate Cancer Biomarker
The TMPRSS2-ERG gene rearrangements are commonly present in prostate cancer. Over-expression of ERG has also been considered as a specific prostate cancer biomarker which is rarely found in other cancers or normal tissues. Compared against current prostate cancer biomarkers, such as serum PSA level, which are often inadequate to accurately predict disease progression, early detection of TMPRSS2-ERG fusion gene, or simply detection of ERG over-expression would provide a significant diagnostic and prognostic value. See reference publication below.
Current methods to detecting TMPRSS2-ERG gene fusion include FISH assay, sequencing, qPCR assay and IHC. OriGene has developed a powerful tool for detecting ERG over-expression using TissueScan™ Tissue cDNA Arrays which contain panels of first strand cDNAs converted from RNA from cancer and normal tissues. This unique qPCR platform allows gene expression survey in hundreds’ cancer tissues within hours. Using our Cancer Survey cDNA Array (Cat# CSRT102) which contains 384 different samples of different cancer types including prostate cancer, our results demonstrate that only prostate cancer (40% of total tested prostate cancer samples) but not other cancer types or normal tissues shows up to 50-fold increase of ERG expression (see attached Fig.), supporting ERG overexpression is a prostate cancer specific phenomenon and could be provided as a specific marker for identifying aggressive prostate cancer subtype and guiding for proper treatment.
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. By MA Rubin et al. Oncogene (2007) 26, 4596–4599.
OriGene Products for ERG:
- TissueScan Tissue cDNA Arrays for gene expression in prostate and other cancer tissues
- ERG gene specific full-length cDNA clones, recombinant proteins, shRNA, and antibodies